Clinical Trial Results:
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Summary
|
|
EudraCT number |
2019-003646-33 |
Trial protocol |
PL PT HU BG CZ IT RO |
Global end of trial date |
26 Oct 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Aug 2024
|
First version publication date |
23 Aug 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
20190008
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04252742 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Amgen Inc.
|
||
Sponsor organisation address |
One Amgen Center Drive, Thousand Oaks, CA, United States,
|
||
Public contact |
IHQ Medical Info-Clinical Trials, Amgen Inc., MedInfoInternational@amgen.com
|
||
Scientific contact |
IHQ Medical Info-Clinical Trials, Amgen Inc., MedInfoInternational@amgen.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
26 Oct 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
26 Oct 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the study was to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
|
||
Protection of trial subjects |
This study was conducted in accordance with the protocol and with consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, applicable International Council for Harmonisation (ICH) Good Clinical Practice and other applicable ICH laws and regulations/guidelines.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Sep 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 23
|
||
Country: Number of subjects enrolled |
Bulgaria: 29
|
||
Country: Number of subjects enrolled |
Czechia: 66
|
||
Country: Number of subjects enrolled |
Hungary: 41
|
||
Country: Number of subjects enrolled |
Italy: 53
|
||
Country: Number of subjects enrolled |
Poland: 278
|
||
Country: Number of subjects enrolled |
Portugal: 9
|
||
Country: Number of subjects enrolled |
Romania: 2
|
||
Country: Number of subjects enrolled |
Spain: 11
|
||
Worldwide total number of subjects |
512
|
||
EEA total number of subjects |
489
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
501
|
||
From 65 to 84 years |
11
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
This study was conducted at 61 study centers in North America and Europe from September 2020 to October 2023. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Eligible adult participants with high frequency episodic migraine (EP) who met specific eligibility criteria during a 2-week run-in period and 4-week baseline period entered the double-blind treatment period (DBTP). The DBTP included a 12-week main-DBTP (M-DBTP) and a 4-week exploratory DBTP (E-DBTP) | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Carer, Assessor | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||
Arm description |
Participants were randomized to receive matching placebo subcutaneously (SC) every 4 weeks (Q4W) for up to 16 weeks in the DBTP. | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||
Dosage and administration details |
Placebo was administered SC Q4W for up to 16 weeks.
|
||||||||||||||||||||||||
Arm title
|
Erenumab 140 mg SC Q4W | ||||||||||||||||||||||||
Arm description |
Participants were randomized to receive 140 mg erenumab SC Q4W for up to 16 weeks in the DBTP. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Erenumab
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for solution for injection in pre-filled syringe
|
||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||
Dosage and administration details |
Erenumab was administered SC Q4W for up to 16 weeks.
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomized to receive matching placebo subcutaneously (SC) every 4 weeks (Q4W) for up to 16 weeks in the DBTP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Erenumab 140 mg SC Q4W
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomized to receive 140 mg erenumab SC Q4W for up to 16 weeks in the DBTP. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants were randomized to receive matching placebo subcutaneously (SC) every 4 weeks (Q4W) for up to 16 weeks in the DBTP. | ||
Reporting group title |
Erenumab 140 mg SC Q4W
|
||
Reporting group description |
Participants were randomized to receive 140 mg erenumab SC Q4W for up to 16 weeks in the DBTP. |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 | ||||||||||||
End point description |
At least moderate headache pain intensity was defined as headache pain intensity reported as 'Moderate' or 'Severe' based on the 3-level headache pain intensity scale. Worst or peak pain intensity during a headache was collected using the e-diary in 3-levels (mild, moderate or severe). The duration of headaches with at least moderate pain intensity was collected. A negative change from baseline indicates a reduction in mean monthly hours of at least moderate headache pain intensity. Change from baseline in mean monthly measurement is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The least squares mean (LSM) estimates of change from baseline in reported headache pain intensity utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [1] - The M-DBTP efficacy analysis set. [2] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
504
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 [3] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-7.95
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-11.45 | ||||||||||||
upper limit |
-4.46 | ||||||||||||
Notes [3] - Nominal p-value is presented without multiplicity adjustment. |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Physical Function Domain Score as Measured by the Migraine Functional Impact Questionnaire (MFIQ) Over Months 1, 2, and 3 | ||||||||||||
End point description |
The MFIQ is a self-administered 26-item instrument measuring the impact of migraine on broader functioning including on Physical Functioning (5 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the past 7 days. A negative change from baseline indicates an improvement in burden. Change from baseline in mean monthly scores is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [4] - The M-DBTP efficacy analysis set. [5] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
483
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 [6] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-7.36
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-10.8 | ||||||||||||
upper limit |
-3.92 | ||||||||||||
Notes [6] - Nominal p-value is presented without multiplicity adjustment. |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Usual Activities Domain Score as Measured by the MFIQ Over Months 1, 2, and 3 | ||||||||||||
End point description |
The MFIQ is a self-administered 26-item instrument measuring the impact of migraine on broader functioning including Impact on Usual Activities (10 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the previous 7 days. A negative change from baseline indicates an improvement in burden. Change from baseline in mean monthly scores is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [7] - The M-DBTP efficacy analysis set. [8] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
483
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 [9] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-7.1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-10.34 | ||||||||||||
upper limit |
-3.87 | ||||||||||||
Notes [9] - Nominal p-value is presented without multiplicity adjustment |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Emotional Functioning Domain Score as Measured by the MFIQ Over Months 1, 2, and 3 | ||||||||||||
End point description |
The MFIQ is a self-administered 26-item instrument measuring the impact of migraine on broader functioning including Impact on Emotional Functioning (5 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the previous 7 days. A negative change from baseline indicates an improvement in burden. Change from baseline in mean monthly scores is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [10] - The M-DBTP efficacy analysis set. [11] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
483
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 [12] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-7.05
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-10.76 | ||||||||||||
upper limit |
-3.34 | ||||||||||||
Notes [12] - Nominal p-value is presented without multiplicity adjustment |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Social Functioning Domain Score as Measured by the MFIQ Over Months 1, 2, and 3 | ||||||||||||
End point description |
The MFIQ is a self-administered 26-item instrument measuring the impact of migraine on broader functioning including Impact on Social Functioning (5 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the previous 7 days. A negative change from baseline indicates an improvement in burden. Change from baseline in mean monthly scores is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [13] - The M-DBTP efficacy analysis set. [14] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
483
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
< 0.001 [15] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-6.82
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-10.37 | ||||||||||||
upper limit |
-3.27 | ||||||||||||
Notes [15] - Nominal p-value is presented without multiplicity adjustment |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Average Duration of at Least Moderate Headache Pain Intensity in Migraine Attacks Occurring Over Months 1, 2, and 3 | ||||||||||||
End point description |
At least moderate headache pain intensity was defined as headache pain intensity reported as 'Moderate' or 'Severe' based on the 3-level headache pain intensity scale. Worst or peak pain intensity during a headache was collected using the e-diary in 3-levels (mild, moderate or severe). The duration of headaches with at least moderate pain intensity during a migraine attack was collected. A negative change from baseline indicates a reduction in mean monthly average duration of at least moderate headache pain intensity during a migraine attack. Change from baseline in mean monthly measurement is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [16] - The M-DBTP efficacy analysis set. [17] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
504
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.013 [18] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-1.07
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1.92 | ||||||||||||
upper limit |
-0.22 | ||||||||||||
Notes [18] - Nominal p-value is presented without multiplicity adjustment. |
|
|||||||||||||
End point title |
Change from Baseline in Mean Monthly Average Peak Migraine Pain Intensity as Assessed by the 11-point Numeric Rating Scale (NRS) Over Months 1, 2, and 3 | ||||||||||||
End point description |
The NRS assesses headache pain intensity ranging from 0 to 10 with a higher score indicating more severe pain. Participants recorded the pain intensity using the e-diary at the headache end-time or in an evening diary entry on a daily basis for an ongoing headache. A negative change from baseline indicates an improvement in pain intensity. Change from baseline in mean monthly scores is the arithmetic mean of the monthly change from baseline values for the months considered with observed data, if there was at least one observed monthly value.
The LSM estimates utilized a linear mixed model which included treatment, visit, treatment-by-visit interaction, and baseline value as covariates and assumed a first-order auto regression covariance structure.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Month 1, Month 2, and Month 3
|
||||||||||||
|
|||||||||||||
Notes [19] - The M-DBTP efficacy analysis set. [20] - The M-DBTP efficacy analysis set. |
|||||||||||||
Statistical analysis title |
LSM Difference: Erenumab - Placebo | ||||||||||||
Comparison groups |
Placebo v Erenumab 140 mg SC Q4W
|
||||||||||||
Number of subjects included in analysis |
504
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.011 [21] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
LSM difference | ||||||||||||
Point estimate |
-0.48
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.85 | ||||||||||||
upper limit |
-0.11 | ||||||||||||
Notes [21] - Nominal p-value is presented without multiplicity adjustment |
|
||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Day 1 to end of the DBTP (up to 16 weeks)
|
|||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Serious adverse events and other adverse events are reported for all participants who received at least one dose of study drug.
|
|||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
26.0
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Erenumab 140 mg SC Q4W
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomized to receive 140 mg erenumab SC Q4W for up to 16 weeks in the DBTP. | |||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomized to receive matching placebo SC QW4 for up to 16 weeks in the DBTP. | |||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No participants experienced any non-serious adverse events above the indicated threshold. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
25 Apr 2022 |
- Updated the secondary and exploratory objectives and endpoints language.
- Updated overall design language to incorporate the qualifying oral triptan-treated migraine attack definition; updated eligibility criteria for the end of the run-in period.
- Updated the key eligibility criteria language.
- Updated schedule of activities language.
- Clarified IP background language.
- Updated the benefit/risk assessment section.
- Updated the prohibited medications section and prior treatment section.
- Clarified that the run-in and baseline periods could not be extended for more than 18 days and 35 days, respectively.
- Updated the subgroup language for the primary and secondary endpoints.
- Updated the statistical analysis methods language. |
||
29 Jun 2022 |
Updated the language in the endpoints. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |